American skullcap (scutellaria lateriflora): A randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers

Phytotherapy Research

Volumn 28, Issue 5, 2014, Pages 692-698

  Brock, Christine ^a   Whitehouse, Julie ^a   Tewfik, Ihab ^a   Towell, Tony ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

American skullcap; anxiety; clinical trial; mood states; phytotherapy; Scutellaria lateriflora

Indexed keywords

HERBACEOUS AGENT; PLACEBO;

ADULT; AGED; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; CLINICAL EFFECTIVENESS; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL HEALTH; MOOD; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SCUTELLARIA LATERIFLORA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

SCUTELLARIA; SCUTELLARIA LATERIFLORA;

AMERICAN SKULLCAP; ANXIETY; CLINICAL TRIAL; MOOD STATES; PHYTOTHERAPY; SCUTELLARIA LATERIFLORA;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; SCUTELLARIA; UNITED STATES; YOUNG ADULT;

EID: 84899476571     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5044     Document Type: Article

References (30)

1. B.N.F. 2008. British National Formulary 55. BMJ Publishing Group and the RPS Publishing: London.
2. Beck AT, Steer RA,. 1993. Beck Anxiety Inventory Manual. The Psychological Corporation. Harcourt Brace & Company: San Antonio, TX.
3. Bergner P,. 2002. Traditional Medicine: Scullcap (Scutellaria lateriflora). Med Herbal 13: 15-17.
4. Brock C, Whitehouse J, Tewfik I, Towell T,. 2013. Identity issues surrounding American skullcap (Scutellaria lateriflora) and an optimised high performance liquid chromatography method to authenticate commercially available products. J Herb Med (http://dx.doi.org/10.1016/j.hermed.2013.02.001).
5. Derderian SS, Bridenbaugh RH, Rajagopal KR,. 1988. Neuropsychologic symptoms in obstructive sleep apnea improve after treatment with nasal continuous positive airway pressure. Chest 94: 1023-7.
6. Felter HW, Lloyd JU,. 1905. Scutellaria lateriflora. King's American Dispensatory (19th edn). Ohio Valey Co: Cincinatti; 1739-41.
7. Frey JM, Mintzer MZ, Rush CR, Griffiths RR,. 1998. Buspirone is differentiated from diazepam in humans using a three-response drug discrimination procedure. Psychopharmacology 138: 16-26.
8. Gafner S, Bergeron C, Batcha LL, et al., 2003. Inhibition of [3H]-LSD binding to 5-HT7 receptors by flavonoids from Scutellaria lateriflora. J Nat Prod 66: 535-537.
9. Greenfield J, Davis JM,. 2004. Medicinal Herb Production Guide. Skullcap (Scutellaria lateriflora L). North Carolina Consortium on Natural Medicines and Public Health: USA.
10. Hui KM, Wang XH, Xue H,. 2000. Interaction of flavones from the roots of Scutellaria baicalensis with the benzodiazepine site. Planta Med 66: 91-93.
11. Joshee N, Patrick TS, Mentreddy RS, Yadav AK,. 2002. Skullcap: Potential medicinal crop. In:, Janick J, Whipkey A, (eds). In Trends in New Crops and New Uses. ASHS Press: Alexandria, VA; 580-586.
12. Kaplan MM,. 2002. Alanine aminotransferase levels: what's normal? Ann Intern Med 137: 49-51.
13. Liao JF, Wang HH, Chen MC, Chen CC, Chen CF,. 1998. Benzodiazepine binding site-interactive flavones from Scutellaria baicalensis root. Planta Med 64: 571-572.
14. Lorr M, McNair DM, Weinstein GJ,. 1963. Early effects of chlordiazepoxide (librium) used with psychotherapy. J Psychiatr Res 1: 257-270.
15. Lorr M, McNair DM, Heuchert JWP, Droppleman LF,. 2005. Profile of Mood States: Standard (Technical Update). Multi-Health Systems Inc.: New York.
16. Luthria DL,. 2006. Significance of sample preparation in developing analytical methodologies for accurate estimation of bioactive compounds in functional foods. J Sci Food Agric 86: 2266-2272.
17. Mitte K, Noack P, Steil R, Hautzinger M,. 2005. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25: 141-50.
18. del Mundo WF, Shepherd WC, Marose TD,. 2002. Use of alternative medicine by patients in a rural family practice clinic. Fam Med 34: 206-212.
19. Pary R, Matuschka PR, Lewis S, Caso W, Lippmann S,. 2003. Generalized anxiety disorder. South Med J 96: 581-6.
20. Pittler MH, Ernst E,. 2003. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev: doi: 10.1002/14651858. CD003383.
21. Prasko J, Dockery C, Horacek J, et al., 2006. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuroendocrinol Lett 27: 473-481.
22. Roche Diagnostics. 2008. Reflotron® GPT (ALT): Rapid results from whole blood (pack insert). Roche Diagnostics GmbH: Mannheim, Germany.
23. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A,. 2011. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol 21: 841-60.
24. Twisk J, Proper K,. 2004. Evaluation of the results of a randomized controlled trial: how to define changes between baseline and follow-up. J Clin Epidemiol 57: 223-228.
25. Uhlenhuth EH, Starcevic V, Qualls C, et al., 2008. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder. Depress Anxiety 25: E18-E26.
26. Upton R, Dayu RH,. 2012. Skullcap Scutellaria lateriflora L.: An American nervine. J Herbal Med 2: 76-96.
27. Wittchen HU, Hoyer J,. 2001. Generalized anxiety disorder: nature and course. J Clin Psychiatry 62 (Suppl 11): 15-9; discussion 20-1.
28. Wohlmuth H, Aulton B, Penman K, et al., Authentication of skullcap (Scutellaria lateriflora L.)-a commonly adulterated medicinal plant. Planta Med 2009; 75: SL25.
29. Wolfson P, Hoffmann DL,. 2003. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med 9: 74-78.
30. Zigmond AS, Snaith RP,. 1983. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67: 361-70.